Home » Posts tagged with » Austria
Paramit to acquire S.I.E SOLUTIONS to expand into Europe

Paramit to acquire S.I.E SOLUTIONS to expand into Europe

Paramit, a US-based manufacturer of medical devices and life science instruments, has signed a deal to acquire Austria-based S.I.E. SOLUTIONS, as part of a strategic expansion into Europe. The financial terms of the deal were not disclosed. S.I.E SOLUTIONS is engaged in providing embedded technology solutions to customers across the healthcare and security technology sectors. […]

Merck completes acquisition of Austrian vaccine developer Themis Bioscience

Pharma giant Merck has wrapped up its previously announced acquisition of Austrian vaccine developer Themis Bioscience. The Austrian company is focused on developing vaccines and immune-modulation therapies for infectious diseases and cancer. Merck announced the deal last month in a move to gain access to Themis Bioscience’s coronavirus vaccine candidate. Read more about Merck acquisition […]

Continue reading …
Themis Bioscience rakes in €40m to advance MV-CHIK Chikungunya vaccine

Themis Bioscience, an Austrian biopharma company, has raised €40 million in a Series D financing round backed by a US/EU Consortium to advance its MV-CHIK Chikungunya vaccine into a phase 3 clinical trial program. The funding round of the Austrian pharma company was co-led by new investors – Farallon Capital and Hadean Ventures. Pharma giant MSD […]

Continue reading …
Greiner Bio-One launches new MiniCollect K2EDTA Capillary Collection Tube

Austrian medical technology manufacturer Greiner Bio-One has launched the newly redesigned MiniCollect K2EDTA Capillary Collection Tube, designed for collecting, transporting and evaluating capillary blood samples. The newly redesigned tube has an integrated scoop which allows easy collection of droplets of blood after skin puncture, thus cutting down on the number of accessories needed. When the […]

Continue reading …
Boehringer Ingelheim acquires oncolytic virus company ViraTherapeutics

German pharma company Boehringer Ingelheim has exercised its option to acquire 100% of Austria-based oncolytic virus company ViraTherapeutics for €210 million in a move to develop next generation viral-based immuno-oncology therapies. In September 2016, Boehringer Ingelheim and ViraTherapeutics entered into a long term collaboration to develop the oncolytic virus therapy platform and also to investigate […]

Continue reading …